Cognition Therapeutics announces promising Phase 2 trial results for CT1812 in dementia with Lewy bodies, with plans for late-stage trials. Cognition Therapeutics, Inc. announced promising topline ...
Cognition Therapeutics, Inc. announced positive results from its Phase 2 trials of zervimesine (CT1812) in treating dementia with Lewy bodies (DLB) and Alzheimer’s disease, indicating significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback